Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria

Nephrology Dialysis Transplantation

Volumn 19, Issue 11, 2004, Pages 2784-2788

  Gæde, Peter ^a   Tarnow, Lise ^a   Vedel, Pernille ^a   Parving, Hans Henrik ^a,b   Pedersen, Oluf ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Glomerular filtration rate; Kidney function; Remission; Risk reduction; Type 2 diabetes mellitus; Urinary albumin excretion rate

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEMOGLOBIN A1C; IRBESARTAN; NIFEDIPINE; PLACEBO; VALSARTAN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; REMISSION; URINARY EXCRETION;

ADULT; AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 8344260643     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh470     Document Type: Article

References (23)

1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Substudy. Lancet 2000; 355: 253-259
2. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-1581
3. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 [Suppl 2]: B54-B64
4. Gæde P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622
5. Nelson RG, Bennett PH, Beek GJ et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335: 1636-1642
6. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
7. Ravid M, Lang R, Rachmani R, Lishner M. Long-term reno-protective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286-289
8. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600
9. Levin SR, Coburn JW, Abraira C et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000; 23: 1478-1485
10. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678
11. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45: s145-s149
12. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45: s174-s178
13. Gæde P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
14. Brochner-Mortensen J, Tougaard L, Fynboe C, Thomsen HG. Individual determination of glomerular filtration rate from plasma creatinine. Scand J Clin Lab Invest 1976; 36: 389-393
15. Feldt-Rasmussen B, Dinesen B, Deckert M. Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 1985; 45: 539-544
16. Gambaro G, Bax G, Fusaro M et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab 2001; 14: 337-342
17. Yokoyama H, Tomonaga O, Hirayama M et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405-411
18. Haffner SM, Mitchell BD, Pugh JA et al. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care 1989; 12: 530-536
19. Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med 1988; 148: 181-186
20. Pugh JA. The epidemiology of diabetic nephropathy. Diabetes Metab Rev 1989; 5: 531-545
21. Ballard DJ, Humphrey LL, Melton LJ et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988; 37: 405-412
22. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003; 26: 911-916
23. Fioretto P, Stehouwer CD, Mauer M et al. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998; 41: 233-236